Articles related to Hepatology

The timing of re-initiation of antithrombotic therapy needs to be individualized based on the severity of the bleed, among other factors. This article reviews the issue and offers tools and guidelines for determining if and when to restart antiplatelet and oral anticoagulant therapy.

The FOENIX*-CCA2 trial, a global phase 2, open-label trial examining 103 patients with unresectable, locally progressed, or metastatic iCCA harboring FGFR2 gene rearrangements including fusions, was the basis for the approval of futibatinib (Lytgobi, Taiho Oncology). Patients in this trial received 20 mg of futibatinib orally once daily until disease progression or intolerable toxicity; the primary end goal was achieved with a 42% objective response rate as determined by an impartial central evaluation. With 72% of responses lasting at least six months, the median response time was 9.7 months.

In this commentary, the editor-in-chief of CCJM considers what is known, and what is still mystery about how the heart and kidneys are modified during chronic heart failure, and discusses how much of our therapy remains empiric and experience-based.

The problem with many of the findings of cirrhosis is you have to specifically look for them or you will miss them. Here’s a tip for helping you not miss them.

The association between lithium use and chronic kidney disease (CKD) has been unclear. This study showed that lithium over the long-term (i.e., 10 years) accelerated the decline in eGFR attributed to aging.

85-year-old woman with Hx of stage 3 chronic kidney disease New onset dyspnea and intermittent mild fever Slight difficulty opening her mouth; no dental caries or cervical lymphadenopathy Elevated CRP Elevated BUN Follow the case as it develops.